| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 148, Issue 8 2357-2362, Copyright © 1992 by American Association of Immunologists
ARTICLES |
MJ Newman, JY Wu, BH Gardner, KJ Munroe, D Leombruno, J Recchia, CR Kensil and RT Coughlin
Cambridge Biotech Corporation, Worcester, MA 01605.
The ability of a saponin adjuvant, QS-21, to induce OVA-specific, class I MHC Ag-restricted CTL was investigated using different forms of soluble OVA and OVA adsorbed onto alum as immunogens. C57BL/6 mice were immunized with soluble native or denatured OVA in formulations that contained increasing quantities of QS-21, and CTL responses were measured using EL4 and E.G7-OVA cells as targets and splenic mononuclear cells as effectors. Ag-specific CTL responses were produced but only if the QS-21 adjuvant was used. Similar responses were induced using alum-adsorbed OVA when mixed with the QS-21 adjuvant but not when used alone. The CTL were specific for an epitope present on the OVA258- 276 synthetic peptide, which contains the dominant CTL epitope recognized by C57BL/6 mice. The CD8+ subpopulation of lymphocytes in immune mice was not increased in spleens but increased significantly in vitro after culture with soluble OVA. The CTL activity of splenic mononuclear cell preparations was totally destroyed by treatment with mAb specific to the CD8 Ag plus complement. The ability of the QS-21 adjuvant to induce class I MHC Ag-restricted CTL after immunization with soluble proteins is a characteristic unique to saponin adjuvants.
This article has been cited by other articles:
|
|
 |
|
  P. B. Chapman, D. Wu, G. Ragupathi, S. Lu, L. Williams, W.-J. Hwu, D. Johnson, and P. O. Livingston Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside Clin. Cancer Res., July 15, 2004; 10(14): 4717 - 4723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Schaed, V. M. Klimek, K. S. Panageas, C. M. Musselli, L. Butterworth, W.-J. Hwu, P. O. Livingston, L. Williams, J. J. Lewis, A. N. Houghton, et al. T-Cell Responses against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants Clin. Cancer Res., May 1, 2002; 8(5): 967 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Naiman, D. Alt, C. A. Bolin, R. Zuerner, and C. L. Baldwin Protective Killed Leptospira borgpetersenii Vaccine Induces Potent Th1 Immunity Comprising Responses by CD4 and gamma delta T Lymphocytes Infect. Immun., December 1, 2001; 69(12): 7550 - 7558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Slingluff Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al. Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes Clin. Cancer Res., October 1, 2001; 7(10): 3012 - 3024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas Blood, March 1, 2001; 97(5): 1370 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Boyaka, M. Marinaro, R. J. Jackson, F. W. van Ginkel, E. Cormet-Boyaka, K. L. Kirk, C. R. Kensil, and J. R. McGhee Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity J. Immunol., February 15, 2001; 166(4): 2283 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. El mir and F. Triebel A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens J. Immunol., June 1, 2000; 164(11): 5583 - 5589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Mikloska, M. Ruckholdt, I. Ghadiminejad, H. Dunckley, M. Denis, and A. L. Cunningham Monophosphoryl Lipid A and QS21 Increase CD8 T Lymphocyte Cytotoxicity to Herpes Simplex Virus-2 Infected Cell Proteins 4 and 27 Through IFN-{gamma} and IL-12 Production J. Immunol., May 15, 2000; 164(10): 5167 - 5176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Timmerman and R. Levy Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine J. Immunol., May 1, 2000; 164(9): 4797 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. St. Clair, B. Shenoy, L. D. Jacob, and A. L. Margolin Cross-linked protein crystals for vaccine delivery PNAS, August 17, 1999; 96(17): 9469 - 9474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Maitre, J. M. Brown, M. Demcheva, J. R. Kelley, M. A. Lockett, J. Vournakis, and D. J. Cole Primary T-Cell and Activated Macrophage Response Associated with Tumor Protection Using Peptide/Poly-N-Acetyl Glucosamine Vaccination Clin. Cancer Res., May 1, 1999; 5(5): 1173 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Shrikant and M. F. Mescher Control of Syngeneic Tumor Growth by Activation of CD8+ T Cells: Efficacy Is Limited by Migration Away from the Site and Induction of Nonresponsiveness J. Immunol., March 1, 1999; 162(5): 2858 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Wong, C. Y. Okada, and R. Levy TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8+ T Cell Response J. Immunol., February 15, 1999; 162(4): 2251 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sasaki, K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. R. Kensil, and K. Okuda Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes J. Virol., June 1, 1998; 72(6): 4931 - 4939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ulmer, J. Donnelly, S. Parker, G. Rhodes, P. Felgner, V. Dwarki, S. Gromkowski, R. Deck, C. DeWitt, A Friedman, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein Science, March 19, 1993; 259(5102): 1745 - 1749. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
